SCHEMBL2747697

SCHEMBL2747697

CC(C)(C)c1cc(F)ccc1S(=O)(=O)O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 1/20 0.42
PTGS2 P35354 1/20 0.42
RBP4 P02753 2/20 0.35
ALDH1A1 P00352 2/20 0.34
HSD11B1 P28845 1/20 0.34
TET2 Q6N021 1/20 0.34
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
MYC P01106 1/20 0.33
PARP1 P09874 1/20 0.33
PDE5A O76074 1/20 0.33
PTGES2 Q9H7Z7 1/20 0.33
P2RY1 P47900 1/20 0.33
PER2 O15055 1/20 0.33
CRY1 Q16526 1/20 0.33
CRY2 Q49AN0 1/20 0.33
MAPK1 P28482 2/20 0.33
MEP1B Q16820 1/20 0.33
TSHR P16473 1/20 0.33
GAA P10253 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3206647 0.85 EPHX2 (0.42) HSD11B1PTGES2PTPN1
Hydrochloric Acid SCHEMBL27308701 0.83 EPHX2 (0.41) HSD11B1PTGES2PTPN1
SCHEMBL18897419 0.82 CCR2 (0.42) PTGS1PTGS2ALDH1A1RAB9ASMN1; SMN2
SCHEMBL2749726 0.81 TRPV4 (0.44) PTGS1PTGS2RBP4ALDH1A1HSD11B1
SCHEMBL30925348 0.81 PTGES2 (0.45) PTGS1PTGS2PTGES2
SCHEMBL7779125 0.78 ALDH1A1 (0.41) ALDH1A1MEN1KMT2ATSHRSMN1; SMN2
SCHEMBL10590409 0.77 PARP1 (0.41) TET2MEN1KMT2AMYCPARP1
SCHEMBL16339268 0.76 TSHR (0.47) PTGS1PTGS2MEN1KMT2AMYC
SCHEMBL795339 0.75 AKR1B1 (0.46) ALDH1A1TET2MAPT
SCHEMBL20362696 0.74 RAB9A (0.33) PTGS1PTGS2ALDH1A1HSD11B1TET2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8178699-B2 Modulators of CCR9 receptor and methods of use thereof PFIZER INC. (US) 2012-05-15 US disclosed
EP-2220065-A2 MODULATORS OF CCR9 RECEPTOR AND METHODS OF USE THEREOF ENCYSIVE PHARMACEUTICALS, INC. (US) 2010-08-25 EP disclosed
US-20100029753-A1 MODULATORS OF CCR9 RECEPTOR AND METHODS OF USE THEREOF ENCYSIVE PHARMACEUTICALS, INC. 2010-02-04 US disclosed
WO-2009017719-A2 MODULATORS OF CCR9 RECEPTOR AND METHODS OF USE THEREOF ENCYSIVE PHARMACEUTICALS, INC. (US) 2009-02-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029753-A1 MODULATORS OF CCR9 RECEPTOR AND METHODS OF USE THEREOF CCR9, CCR1, CCR4 PTGS1 1830/4885PTGS2 2266/4885RBP4 1334/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.